United States
Vascular Endothelial Growth Factor C (C152S mutant) (rat) (recombinant) (His)
| RLT-R20-017-C020 | 20 µg | 215.00 USD |  |
||
This mutant is lacking binding to VEGFR-2 (KDR) and can serve as a unique tool to investigate the signal transduction of VEGF-C via VEGFR-3 (Flt-4). According to the high degree of homology between growth factors of mammalian species, the protein can also be used for experiments with human cells and for further in vitro and in vivo experiments with other cells and species.
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Product Literature References
Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats: J. Krishnan, et al.; Cancer Res. 63, 713 (2003), Abstract;
Lymphangiogenic gene therapy with minimal blood vascular side effects: A. Saaristo, et al.; J. Exp. Med. 196, 719 (2002), Abstract;
Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2: V. Kirkin, et al.; Eur. J. Biochem. 268, 5530 (2001), Abstract; Full Text
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice: T. Veikkola, et al.; EMBO J. 20, 1223 (2001), Abstract; Full Text
another CS2 website
©2016 Axxora, LLC.,
